Cor Vasa 2019, 61(3):e334-e340 | DOI: 10.33678/cor.2019.019

(Secondary prevention of coronary heart disease and peripheral artery disease combining antiaggregation and anticoagulation therapy. Expert consensus statement of the Czech Society of Cardiology, the Czech Society of Internal Medicine and the Czech Society of Angiology to the outcomes of COMPASS trial)

Petr Widimskýa, Debora Karetováb, Richard Češkac, Miloš Táborskýd, Hana Rosolováe, Jean-Claude Lubandab, Aleš Linhartb
a Kardiocentrum, 3. lékařská fakulta Univerzity Karlovy a Fakultní nemocnice Královské Vinohrady, Praha
b II. interní klinika kardiologie a angiologie, 1. lékařská fakulta Univerzity Karlovy a Všeobecná fakultní nemocnice v Praze, Praha
c Centrum preventivní kardiologie, III. interní klinika, 1. lékařská fakulta Univerzity Karlovy a Všeobecná fakultní nemocnice v Praze, Praha
d I. interní klinika - kardiologická, Lékařská fakulta Univerzity Palackého a Fakultní nemocnice Olomouc, Olomouc
e Centrum preventivní kardiologie, II. interní klinika, Lékařská fakulta Univerzity Karlovy a Fakultní nemocnice Plzeň, Plzeň

Received: April 25, 2019; Accepted: April 28, 2019; Published: June 21, 2019  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Widimský P, Karetová D, Češka R, Táborský M, Rosolová H, Lubanda J, Linhart A. (Secondary prevention of coronary heart disease and peripheral artery disease combining antiaggregation and anticoagulation therapy. Expert consensus statement of the Czech Society of Cardiology, the Czech Society of Internal Medicine and the Czech Society of Angiology to the outcomes of COMPASS trial). Cor Vasa. 2019;61(3):e334-340. doi: 10.33678/cor.2019.019.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Bruthans J, Cífková R, Lánská V, et al. Explaining the decline in coronary heart disease mortality in the Czech Republic between 1985 and 2007. Eur J Prev Cardiol 2014;21:829-839. Go to original source... Go to PubMed...
    2. Piepoli MF, Hoes AW, Agewall S, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice. The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts). Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J 2016;37:2315-2381. Go to original source... Go to PubMed...
    3. Kotseva K, Wood D, De Bacquer D, et al. EUROASPIRE IV: a European Society of Cardiology survey on the lifestyle, risk factors and therapeutic managements of coronary patients from 24 European countries. Eur J Prev Cardiol 2016;23:636-648. Go to original source... Go to PubMed...
    4. Ibanez B, James S, Agewall S, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 2018;39:119-177. Go to original source... Go to PubMed...
    5. Catapano AL, Graham I, De Backer G, et al. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. Eur Heart J 2016;37:2999-3058. Go to original source... Go to PubMed...
    6. Williams B, Mancia I, Spiering W, et al. 2018 ESC/EHS Guidelines for the management of arterial hypertension. Eur Heart J 2018;39:3021-3104. Go to original source... Go to PubMed...
    7. Bhatt DL, Steg PG, Ohman EM, et al. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA 2006;295:180-189. Go to original source... Go to PubMed...
    8. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996;348:1329-1339. Go to original source... Go to PubMed...
    9. Hiatt WR, Fowkes FG, Heizer G, et al. Ticagrelor versus Clopidogrel in Symptomatic Peripheral Artery Disease. EUCLID Trial Steering Committee and Investigators. N Engl J Med 2017;376:32-40. Go to original source... Go to PubMed...
    10. Aboyans V, Ricco JB, Bartelink MEL, et al. 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in Collaboration With the European Society for Vascular Surgery (ESVS): Document Covering Atherosclerotic Disease of Extracranial Carotid and Vertebral, Mesenteric, Renal, Upper and Lower Extremity Arteries. Eur Heart J 2018;39:763-816. Go to original source... Go to PubMed...
    11. Mega JL, Braunwald E, Wiviott SD, et al., ATLAS ACS 2-TIMI 51Investigators. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med 2012;366:9-19. Go to original source... Go to PubMed...
    12. Bosch J, Eikelboom JW, Connolly SJ, et al. Rationale, Design and Baseline Characteristics of Participants in the Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) Trial. Can J Cardiol 2017;33:1027-1035. Go to original source... Go to PubMed...
    13. Hurlen M, Abdelnoor M, Smith P, et al. Warfarin, Aspirin or Both After Myocardial Infarction. N Engl J Med 2002. 347: 969-974. Go to original source... Go to PubMed...
    14. Eikelboom JW, Connolly SJ, Bosch J, et al.; COMPASS Investigators. Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. N Engl J Med 2017;377:1319-1330. Go to original source... Go to PubMed...
    15. Connolly SJ, Eikelboom JW, Bosch J, et al.; COMPASS Investigators. Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet 2018;391:205-218. Go to original source... Go to PubMed...
    16. Lamy A, Eikelboom J, Sheth T, et al. Rivaroxaban, Aspirin, or Both to Prevent Early Coronary Bypass Graft Occlusion: The COMPASS-CABG Study. J Am Coll Cardiol 2019;73:121-130. Go to original source... Go to PubMed...
    17. Anand SS, Bosch J, Eikelboom JW, et al.; COMPASS Investigators. Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet 2018;391:219-229. Go to original source... Go to PubMed...
    18. Randomised double-blind trial of fixed low-dose warfarin with aspirin after myocardial infarction. Coumadin Aspirin Reinfarction Study (CARS) Investigators. [No authors listed] Lancet 1997;350:389-396.
    19. Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. The Medical Research Council's General Practice Research Framework. [No authors listed] Lancet 1998;351:233-241. Go to original source...
    20. Herlitz J, Holm J, Peterson M, et al., LoWASA study group. Effect of fixed low-dose warfarin added to aspirin in the long term after acute myocardial infarction; the LoWASA Study. Eur Heart J 2004;25:232-239. Go to original source... Go to PubMed...
    21. Hurlen M, Abdelnoor M, Smith P, et al. Warfarin, aspirin, or both after myocardial infarction. N Engl J Med 2002;347:969-974. Go to original source... Go to PubMed...
    22. Andreotti F, Testa L, Biondi-Zoccai GG, Crea F. Aspirin plus warfarin compared to aspirin alone after acute coronary syndromes: an updated and comprehensive meta-analysis of 25,307 patients. Eur Heart J 2006;27:519-526. Go to original source... Go to PubMed...
    23. Alexander JH, Lopes RD, James S, et al., for the APPRAISE-2 Investigators. Apixaban with Antiplatelet Therapy after Acute Coronary Syndrome. N Engl J Med 2011;365:699-708. Go to original source... Go to PubMed...
    24. Oldgren J, Budaj A, Granger CB, et al.; RE-DEEM Investigators. Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial. Eur Heart J 2011;32:2781-2789. Go to original source... Go to PubMed...
    25. Bonaca MP, Bhatt DL, Cohen M, et al.; for the PEGASUS-TIMI 54 Steering Committee and Investigators. Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction. N Engl J Med 2015;372:1791-1800. Go to original source... Go to PubMed...

    This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0), which permits non-comercial use, distribution, and reproduction in any medium, provided the original publication is properly cited. No use, distribution or reproduction is permitted which does not comply with these terms.


    Return to the content


    Cor et Vasa

    You are accessing a site intended for medical professionals, not the lay public. The site may also contain information that is intended only for persons authorized to prescribe and dispense medicinal products for human use.

    I therefore confirm that I am a healthcare professional under Act 40/1995 Coll. as amended by later regulations and that I have read the definition of a healthcare professional.


    No
    Yes